Vanguard Group Inc. Purchases 293,740 Shares of OPKO Health, Inc. $OPK

Vanguard Group Inc. raised its stake in OPKO Health, Inc. (NASDAQ:OPK) by 1.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 29,500,071 shares of the biotechnology company’s stock after buying an additional 293,740 shares during the period. Vanguard Group Inc. owned about 3.72% of OPKO Health worth $48,970,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. XTX Topco Ltd lifted its stake in shares of OPKO Health by 58.8% in the 1st quarter. XTX Topco Ltd now owns 309,290 shares of the biotechnology company’s stock valued at $513,000 after purchasing an additional 114,486 shares during the period. GSA Capital Partners LLP raised its stake in OPKO Health by 24.2% during the 1st quarter. GSA Capital Partners LLP now owns 1,343,701 shares of the biotechnology company’s stock worth $2,231,000 after buying an additional 261,495 shares during the period. Inspire Advisors LLC purchased a new stake in shares of OPKO Health in the first quarter worth approximately $78,000. Oak Thistle LLC purchased a new stake in shares of OPKO Health in the first quarter worth approximately $26,000. Finally, Private Advisor Group LLC raised its stake in shares of OPKO Health by 56.7% in the first quarter. Private Advisor Group LLC now owns 55,301 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 20,000 shares during the last quarter. Institutional investors own 64.63% of the company’s stock.

Insider Activity

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 675,000 shares of the stock in a transaction dated Friday, August 8th. The stock was purchased at an average cost of $1.32 per share, for a total transaction of $891,000.00. Following the completion of the acquisition, the chief executive officer owned 214,676,448 shares of the company’s stock, valued at approximately $283,372,911.36. This trade represents a 0.32% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 49.69% of the company’s stock.

Analyst Upgrades and Downgrades

OPK has been the subject of several recent analyst reports. Zacks Research raised OPKO Health from a “strong sell” rating to a “hold” rating in a report on Thursday, August 14th. Barrington Research restated an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a research report on Thursday, May 1st. Wall Street Zen downgraded OPKO Health from a “hold” rating to a “sell” rating in a research report on Monday, May 5th. Finally, LADENBURG THALM/SH SH upgraded OPKO Health to a “strong-buy” rating in a research report on Tuesday, July 8th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, OPKO Health currently has an average rating of “Moderate Buy” and an average target price of $2.75.

OPKO Health Stock Performance

OPKO Health stock opened at $1.39 on Tuesday. The stock’s 50 day simple moving average is $1.33 and its two-hundred day simple moving average is $1.46. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.02 and a current ratio of 3.41. The stock has a market cap of $1.10 billion, a price-to-earnings ratio of -5.56 and a beta of 1.19. OPKO Health, Inc. has a fifty-two week low of $1.11 and a fifty-two week high of $2.0350.

OPKO Health (NASDAQ:OPK) last released its earnings results on Thursday, July 31st. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.07). OPKO Health had a negative net margin of 26.68% and a negative return on equity of 13.17%. The business had revenue of $156.80 million for the quarter, compared to analysts’ expectations of $165.74 million. During the same quarter in the previous year, the business posted ($0.01) earnings per share. OPKO Health’s revenue for the quarter was down 13.9% on a year-over-year basis. As a group, analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.